» Articles » PMID: 29177795

Myocardial Injury After Endovascular Revascularization in Critical Limb Ischemia Predicts 1-year Mortality: a Prospective Observational Cohort Study

Abstract

Background: Patients with critical limb ischemia (CLI) are at increased risk of cardiovascular complications and mortality. To determine (1) incidence of myocardial injury following endovascular revascularization, and (2) relationship between myocardial injury with 1-year mortality and major adverse cardiovascular events (MACE; i.e., composite of myocardial infarction, stroke, and death).

Methods And Results: Single-center, prospective cohort study of CLI patients ≥ 45 years of age, who underwent endovascular revascularization with overnight hospitalization. High-sensitive troponins T (hsTnTs) were measured on admission, 3-6 h after endovascular revascularization and the subsequent morning. Myocardial injury after endovascular revascularization was defined as an hsTnT ≥ 14 ng/L with a relative increase ≥ 30% from the baseline value. We also evaluated other myocardial injury hsTnT thresholds (i.e., ≥ 30, ≥ 40, ≥ 60, and ≥ 80 ng/L). 239 consecutive patients (56% male, mean age 71.5 ± 10.1 years) were included; one patient was lost to follow-up. At 1 year, there were 34 deaths (14.2%), and 48 MACE (20.5%). Myocardial injury with the hsTnT threshold of 14 ng/L and relative increase by ≥ 30% from the baseline level occurred in 61 patients (25.5%). Myocardial injury was independently associated with 1-year mortality ([aHR], 2.44; 95% CI 1.18-5.06, for hsTnT ≥ 14 ng/L to aHR, 3.34; 95% CI 1.29-8.65 for hsTnT ≥ 80 ng/L). Myocardial injury was also independently associated with 1-year MACE ([AOR] 2.89; 95% CI 1.41-5.92 for hsTnT ≥ 14 ng/L to AOR, 6.69; 95% CI 2.17-20.68 for hsTnT ≥ 80 ng/L). 85.2% patients who had myocardial injury did not have ischemic clinical symptoms or electrocardiography changes. In sensitive analysis with exclusion of symptomatic patients that developed myocardial injury for the hsTnT ≥ 14 ng/L threshold, both the 1-year mortality (aHR: 2.19; CI 1.02-4.68; p = 0.04), and 1-year MACE (OR 2.25; CI 1.06-4.77; p = 0.036) remained significant.

Conclusions: Myocardial injury is common following endovascular revascularization for CLI and associated with the risk of 1-year mortality and MACE.

Citing Articles

Postoperative Myocardial Infarction after Non-Cardiac Surgery: An Update.

Rostagno C, Craighero A J Clin Med. 2024; 13(5).

PMID: 38592265 PMC: 10932291. DOI: 10.3390/jcm13051473.


Incidence and risk factors of postoperative acute myocardial injury in noncardiac patients: A systematic review and meta-analysis.

Chang Y, Zhou M, Huang J, Wang Y, Shao J PLoS One. 2023; 18(6):e0286431.

PMID: 37319136 PMC: 10270363. DOI: 10.1371/journal.pone.0286431.


Mast cell activation and degranulation in acute artery injury: A target for post-operative therapy.

Harper R, Fang F, San H, Negro A, St Hilaire C, Yang D FASEB J. 2023; 37(7):e23029.

PMID: 37310585 PMC: 11095138. DOI: 10.1096/fj.202201745RR.


Long-term major adverse cardiovascular events following myocardial injury after non-cardiac surgery: meta-analysis.

Strickland S, Quintela E, Wilson M, Lee M BJS Open. 2023; 7(2).

PMID: 37104754 PMC: 10129390. DOI: 10.1093/bjsopen/zrad021.


Cardiac Troponins for the Clinical Management of Patients with Claudication and without Cardiac Symptoms.

Mouselimis D, Hagstotz S, Lichtenberg M, Donas K, Heinrich U, Avranas K J Clin Med. 2022; 11(24).

PMID: 36555902 PMC: 9785062. DOI: 10.3390/jcm11247287.


References
1.
Hikita H, Shigeta T, Kimura S, Takahashi A, Isobe M . Coronary Artery Disease Severity and Cardiovascular Biomarkers in Patients with Peripheral Artery Disease. Int J Angiol. 2015; 24(4):278-82. PMC: 4656161. DOI: 10.1055/s-0035-1555133. View

2.
Giannitsis E, Spanuth E, Horsch A, Kleber M, Koch W, Grammer T . High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med. 2013; 51(10):2019-28. DOI: 10.1515/cclm-2012-0786. View

3.
van Waes J, Nathoe H, de Graaff J, Kemperman H, de Borst G, Peelen L . Myocardial injury after noncardiac surgery and its association with short-term mortality. Circulation. 2013; 127(23):2264-71. DOI: 10.1161/CIRCULATIONAHA.113.002128. View

4.
Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776. View

5.
Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67. DOI: 10.1016/j.jvs.2006.12.037. View